Introduction
Consistent with its role as a central regulator of cell growth and division, the p53 tumor-suppressor protein responds to a wide variety of cellular stresses, including hypoxia (Alarcon et al. , 1999) , nucleotide starvation (Linke et al., 1996; Chernova et al., 1998) , oncogene expression (Lowe, 1999) and DNA damage (Appella and Anderson, 2001) . p53 activation involves an increase in protein levels as a well as an increase its ability to interact with the transcriptional machinery (Ljungman, 2000) . The biochemical modifications that regulate p53 reflect the upstream signaling pathways activated (Agarwal et al., 1998a, b) . In many cases, multiple, divergent pathways activate p53, depending on the type and magnitude of each stress (Ashcroft et al., 2000) .
p53 induces cell cycle arrest in the G1, G2 and S phases of the cell cycle (Agarwal et al., 1995 (Agarwal et al., , 1998a . A major effector of G1 and G2 arrest is the cyclin-dependent kinase (CDK) inhibitor p21 (el-Deiry et al., 1993; Harper et al., 1993) , which binds to and inactivates cyclin-CDK complexes, ultimately leading to the hypophosphorylation of Rb family members, which bind to E2F family members to repress the cyclin B1 and cdc2 genes. These genes, among many others, must be expressed for entry into mitosis (Hermeking et al., 1997; Innocente et al., 1999; Kaelin, 1999; Taylor et al., 1999) . p53 also initiates apoptosis, DNA repair and antiangiogenesis mechanisms through transcriptional activation of an ever increasing number of genes (Vogelstein et al., 2000) and through the newly discovered role of p53 in mediating the release of cytochrome c from the mitochondria (Mihara et al., 2003) .
Studies using oligonucleotide microarrays have continued to uncover important p53-regulated genes. In one such study (Zhao et al., 2000) , the induction of p53 resulted in the regulated expression, as expected, of genes involved in growth arrest and apoptosis. However, genes encoding growth factors, growth factor inhibitors, proteins having cytoskeletal functions, an involvement in adhesion, or components of the extracellular matrix were also significantly modulated. Furthermore, the pattern of stimulation or repression of transcription was specific for each p53-inducing agent. Different DNAdamaging agents affected differentially both the magnitude and kinetics of induction or repression.
The regulation of p53 involves a complex network of proteins, with MDM2 being the primary regulator of p53 protein levels and activity (Alarcon-Vargas and Ronai, 2002) . The importance of MDM2 is demonstrated by the phenotype of mdm2-null mice, which die early in embryogenesis due to deregulated p53 expression (Jones et al., 1995; Montes de Oca Luna et al., 1995) . MDM2 regulates p53 by binding to and shielding the transcriptional activation domain, as well as by promoting rapid proteosome-mediated degradation (Momand et al., 1992; Oliner et al., 1993; Haupt et al., 1997; Kubbutat et al., 1997) . The MDM2-mediated degradation of p53 requires that it act as an E3 ubiquitin ligase (Fang et al., 2000) . Ubiquitinated p53 is exported to the cytoplasm, where it undergoes proteosomal degradation (Honda et al., 1997; Boyd et al., 2000; Geyer et al., 2000) . The mdm2 gene itself also contains a p53-dependent promoter and is transcriptionally regulated by p53, following challenge of cells by various stresses (Wu et al., 1993) . Therefore, a feedback loop is present in which p53 transcriptionally activates its own negative regulator.
A number of mechanisms block the interaction between MDM2 and p53 immediately following DNA damage. First, the induction of MDM2 following treatment with high doses of UV or camptothecin is delayed or even repressed, even though p53 is stabilized immediately and other p53-regulated genes, such as p21, are upregulated quickly (Perry et al., 1993; Wu and Levine, 1997; Reinke and Lozano, 1997; Saucedo et al., 1998; Ashcroft et al., 2000) . Second, the activation of a number of kinases has been implicated in the phosphorylation of both p53 and MDM2 (reviewed in Ljungman, 2000) . Many of these phosphorylation events increase the half-life and activity of p53 by decreasing its ability to interact with MDM2, thereby allowing p53 to assert its effects on growth suppression, DNA repair and apoptosis (Mayo et al., 1997; Shieh et al., 1997 Shieh et al., , 1999 Shieh et al., , 2000 Chehab et al., 2000; Stark, 2001, 2002) . Third, a number of proteins bind to either p53 or MDM2 and disrupt the negative regulation of p53 by MDM2. p14ARF (p19ARF in mice) is produced from an alternative reading frame of the CDKN2A locus that also encodes cyclin-cdk inhibitor INK4A (Quelle et al., 1995; Stott et al., 1998) . While the coding transcripts of INK4a and ARF are derived from common exons, the primary amino-acid sequences of both proteins are unique. Thus, the loss of p14ARF and/ or Ink4A occurs frequently in human cancers and disrupts the p53 and/or Rb pathways (Sherr, 2000) . In tumor cell lines, there is an inverse correlation between ARF and p53 expression, arguing that the functionality of the ARF-p53 connection must be disrupted for tumorigenesis to occur . In addition, ARF-null mice develop at an early age spontaneous tumors that lack mutation or deletion of p53 (Kamijo et al., 1997; . Loss of ARF also enhances MDM2-mediated defects in mammary gland development, independently of p53 or E2F1 (Lundgren et al., 1997; Foster and Lozano, 2002) . Furthermore, ARF induces cell-cycle arrest in the absence of both p53 and MDM2 (Weber et al., 2000) and promotes hyaloid vascular regression independently of p53 (McKeller et al., 2002) . ARF expression is induced by MYC , RAS , E2F1 , ABL (Cong et al., 1999) or E1A (de Stanchina et al., 1998) and the resulting upregulation of p53 by these proteins requires ARF expression. Furthermore, whereas expression of ARF alone induces cell cycle arrest predominantly, MYC-or E1A-mediated ARF expression results in apoptosis, an outcome solely dependent on the presence of ARF (de Stanchina et al., 1998; Zindy et al., 1998) . ARF binds to MDM2, resulting in the sequestration of MDM2 to the nucleolus (Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998; Weber et al., 1999) . The resulting MDM2-ARF complex is unable to mediate nucleocytoplasmic shuttling of p53 (Tao and Levine, 1999) or act as an E3 ligase to ubiquitinate p53 (Honda and Yasuda, 1999; Midgley et al., 2000) .
In the present study, we have utilized gene arrays to examine p53-mediated transactivation following DNA damage or p14ARF induction in U2OS cells. Whereas the forms of p53 induced by DNA damage are phosphorylated on all the six serine residues examined, p53 stabilized by p14ARF is phosphorylated detectably only at serine 392. Despite these significant differences, p53-mediated transactivation of the majority of target genes was surprisingly similar. However, a small number of genes were differentially regulated by each treatment.
Results

p53 activation by the induction of p14ARF or with adriamycin treatment
A number of studies have demonstrated differential expression of p53 target genes in response to different cellular stresses (Komarova et al. , 1998; Zhao et al., 2000) . Furthermore, both the extent and specificity of p53 modification (and stabilization) are determined by the type and magnitude of the applied stress (Ashcroft et al., 2000) . However, little is known about the status of p53 stabilized by p14ARF induction. To study further the difference in p53 regulation by treatments that activate p53 through DNA damage-activated pathways or through pathways that do not involve DNA damage, a derivative of the osteosarcoma cell line U2OS containing wild-type p53 and a p14ARF cDNA under the control of an inducible promoter (NARF2; Stott et al., 1998) was analysed. NARF2 cells were treated with increasing concentrations of IPTG, 50 ng/ml adriamycin or 1 mg/ml camptothecin and cell lysates were analysed (Figure 1a) . Treatment of either NARF2 or parental U2OS cells with either adriamycin or camptothecin resulted in similar increases in p53, p21 and MDM2 and demonstrated that the p14ARF transgene does not contribute to p53 regulation in the absence of IPTG. Additionally, p53, p21 and MDM2 were induced by IPTG only in the NARF2 cells, as expected.
To insure that the increase in p21 was due specifically to p53-dependent transcription, we examined p21 and MDM2 protein and mRNA levels 4, 8 and 24 h after adding IPTG or 24 h after adding adriamycin. Again, the p53 protein was stabilized equivalently and comparable increases in the mRNAs for p21 and mdm2 were observed (Figures 1b and c) . In contrast, ablation of p53 function using GSE56, a genetic suppressor of p53 (Ossovskaya et al., 1996) , resulted in decreased basal p21 expression and loss of p14ARF-induced p21 expression (see below). p53 stabilized by p14ARF or adriamycin is differentially phosphorylated p53 is stabilized and activated similarly by p14ARF or adriamycin (Figure 1 ). Since p53 is not phosphorylated on serine 15 following its stabilization by the adenoviral E1A protein (de Stanchina et al., 1998) , but is phosphorylated extensively following DNA damage (Appella and Anderson, 2001) , we thought it likely that p53 would be modified differently in response to p14ARF or adriamycin. In order to evaluate in a global manner post-translational modifications, such as phosphorylation, that change the charge of p53, we examined the migration of p53 subspecies in 2D gels. In untreated NARF2 cells, several forms of p53 that have different isoelectric points are evident (data not shown). Following the induction of p14ARF, the same subspecies are present, but increased in amount, and, in addition, there is a specific increase in two subspecies that have less negative charge, consistent with decreased phosphorylation. In contrast, as expected, treatment with adriamycin leads to an increase in the average negative charge (data not shown). The existence of differentially charged p53 species in the 2D analysis indicates that overall p53 modification is fairly complex. The net charge of p53 reflects the possible modification by phosphorylation, acetylation, ubiquitination and sumoylation, among others. Therefore, to focus our studies, we examined six serine residues known to be sites of modification by using phosphospecific antibodies. As previously described (Appella and Anderson, 2001) , serines 6, 9, 15, 20, 37 and 392 were phosphorylated following treatment with adriamycin ( Figure 2 ). In contrast, p53 stabilized by p14ARF was not modified detectably on any of the five N-terminal serines; only C-terminal serine 392 was phosphorylated significantly. These observations demonstrate that p53-dependent transactivation of the p21 and mdm2 genes does not depend on the phosphorylation of p53 on the five N-terminal residues examined. Our finding that p53 is not detectably phosphorylated on serines 15 or 20 upon p14ARF induction differ with previously published results (Rocha et al. 2003) . In our studies, induction of p53 in response to p14ARF was compared with induction following treatment with a DNA-damaging agent known to cause heavy phosphorylation of p53. We consistently observed that the five Nterminal sites of p53 were not phosphorylated in response to p14ARF.
To further characterize the status of p53 in NARF2 cells following IPTG or adriamycin treatment further, p53 was immunoprecipitated to examine its interaction with MDM2. Much more MDM2 was bound to p53 following the induction of p14ARF than after treatment with adriamycin ( Figure 3 ), probably reflecting the efficient disruption of p53-MDM2 complexes that follows the phosphorylation of p53 in response to DNA damage. Since the kinases that respond to DNA damage are not likely to be activated in response to the induction of p14ARF, p53-MDM2 complexes would not be disrupted as efficiently in the latter situation. It is important to note that p14ARF is not found in p53-MDM2 complexes and that the amount of MDM2 bound to p53 in the presence of p14ARF, although significantly greater than the amount bound following adriamycin treatment, represents less than 5% of the total amount of MDM2 in the cell. To examine whether the p53 induced by p14ARF could be activated further by post-translational modifications stimulated by treatment with adriamycin, NARF2 cells were treated with IPTG or adriamycin singly, or sequentially with IPTG and then adriamycin (Figure 4) . No increase in p21 was observed following either combined treatment. This observation suggests that, once p53 is stabilized and free from MDM2, DNAdamage-induced post-translational modification does not activate it further for transcription of p21. Therefore, although the patterns of p53 phosphorylation and MDM2 binding are distinct following each treatment, the transcriptional activities of p53 towards mdm2 and p21 are strikingly similar.
Global examination of activation by p53 genes in response to p14ARF or adriamycin A cDNA array representing a comprehensive collection of p53-regulated genes was constructed. cDNAs corresponding to previously reported p53-responsive genes, as well as genes identified in our own Affymetrix experiments, were spotted in duplicate on glass slides (Materials and methods). Cy-3-labeled total RNA from untreated NARF2 cells was hybridized to the arrays in competition with Cy-5-labeled total RNAs from NARF2 cells treated with IPTG or adriamycin (data not shown). Each spot was individually examined for reliability before quantitation with GenePix software. Arbitrarily, we designated a gene with two-fold or greater induction as upregulated and a gene with 1.7-fold repression or more as downregulated. Northern analysis of a number of genes has demonstrated that the extents of induction or repression were usually underestimated in the array experiments. Following comparison of the separate lists, most genes were induced or repressed similarly by p14ARF or adriamycin, indicating that the differentially modified p53 molecules act similarly on many p53-responsive promoters. To confirm and extend the results of the array analysis, Cy-3-labeled total RNA from NARF2 cells treated with Figure 3 p53-MDM2 interactions following induction of p14ARF or treatment with adriamycin. NARF2 cells were treated with IPTG (0.1 mM) or adriamycin (50 ng/ml) for 24 h. p53 was immunoprecipitated from cell lysates by using a goat polyclonal antibody. Immunoprecipitates (right side) and 5% input of the cell lysates (left side) were analysed by the Western method for p53 (monoclonal p53 antibody DO-1/HRP conjugate), MDM2, p14ARF or actin Figure 4 Adriamycin treatment does not activate p14ARF-induced p53 further. NARF2 cells were untreated (two plates) or treated with IPTG (0.1 mM, two plates) for 24 h. One untreated and one IPTG-treated plate were treated with 50 ng/ml adriamycin ('Adr' and 'p14ARF þ Adr') for an additional 24 h, while the other two plates were not treated with adriamycin ('untreated' and 'p14ARF') . Cell lysates were analysed by the Western method for p14ARF, p53, p21 and actin Figure 2 Differentially modified forms of p53 regulate mdm2 and p21 gene expression similarly. NARF2 cells were treated with IPTG (0.1 mM) or adriamycin (50 ng/ml) for 24 h. Cell lysates were analysed by the Western method using antibodies that recognize specific phosphorylated serine residues of p53 (pSer 6, 9, 15, 20, 37, 392) . Total p53 was detected with a polyclonal p53 antibody, while an antibody to actin was used to normalize loading. Each phosphoantibody analysis was made using a separate membrane made from the same extracts, to avoid problems associated with stripping and reprobing the same membrane. The total amount of p53 was similar in all experiments IPTG was hybridized competitively to the arrays with Cy-5-labeled total RNA from cells treated with adriamycin. In seven separate experiments, including some in which the chromophores were swapped, the expression of most genes was indistinguishable after p53 induction by p14ARF or adriamycin. Many of these genes are known p53 targets, for example, apoptosis inhibitor 4 (survivin), gadd45, cdc2, cyclin B1, p53AIP1, p53R2, plasminogen activator inhibitor I, insulin-like growth factor binding protein 3, topoisomerase II and, of course, p21 and mdm2.
Differential regulation of specific genes by p14ARF and adriamycin
Selected genes that were differentially regulated reproducibly on the arrays, such as Histone 2BQ, Primase P1, Replication factor C (RFC4) and cFABP, for example (Figure 5a ), were confirmed by macroarray (Figure 5c ) or Northern analyses ( Figure 6 ). Cells containing either control vector (pLXSN) or GSE56, a genetic suppressor element encoding amino acids 275-368 of the p53 cDNA that eliminates p53 function (Ossovskaya et al., 1996; Figure 5b ), were treated with either IPTG or adriamycin to induce p53. Total RNA was harvested at 24 and 48 h and 32 P-dCTP-labeled using reverse transcription as previously described (Schlaak et al., 2002) . Each sample was hybridized to a separate spotted array containing the purified cDNAs of interest. Most of the genes examined were more significantly repressed following the induction of p14ARF than in response to treatment with adriamycin ( Figure 5c ; see AI4, E2-C, PECC, RB-bp4, KIAA0101, Primase P1, RFC 4 and cFABP). These genes were not repressed in cells lacking p53 activity. Phosphoglycerate kinase-1 (PGK-1) serves as a loading control.
We examined AIP4(survivin) because it is one of the few genes previously shown to be directly repressed by p53 bound to the promoter, rather than by p21-mediated repression. However, repression of AIP4(survivin) also occurred less efficiently upon adriamycin treatment relative to p14ARF induction. Histone family member H1.2 and gadd45 are upregulated by both treatments although Histone H1.2 and Histone 2BQ induction appear to be independent of p53 ( Figure 5c ). Figure 5 A p53-specific array to examine global p53-dependent gene expression. Human cDNAs, either known to be p53 targets or newly identified in our Affymetrix experiments, were spotted in duplicate onto glass slides. (a) Cy-3-labeled total RNA from NARF2 cells treated with IPTG was hybridized competitively to the arrays with Cy-5-labeled total RNA from NARF2 cells treated with adriamycin. The slides were scanned on a Genepix scanner and analysed with Genepix and Genespring software. (b) Lysates from NARF2 and GSE56 (NARF2) were analysed by the Western method to demonstrate the inactivation of p53 (loss of p21 expression) by GSE56 overexpression in both untreated and IPTG-treated cells. (c) Gel-purified cDNAs were spotted in triplicate on Hybond-N þ membranes, as described by Schlaak et al. (2002) . Total RNAs from IPTG-and adriamycin-treated cells were labeled with 32P-dCTP. Each labeled RNA sample was incubated with a separate array as described for our Northern analyses A number of genes examined by macroarray and others identified as differently regulated were further examined by Northern analysis. Again, cFABP expression was repressed by p14ARF but not adriamycin (Figure 6a ). Furthermore, cFABP expression was enhanced in dividing cells following the expression of GSE56. Ubiquitin-carrier E2-C, Pecc and HP10461 (also known as oncogene ECT2) were more significantly repressed following the induction of p14ARF than in response to treatment with adriamycin ( Figure 6b ). ESDN and KIAA0247 were induced by both treatments, similarly to p21 and mdm2, while CTGF was induced specifically by p14ARF (Figure 6b) . Additionally, as seen with cFABP, GSE56 was able to diminish CTGF expression in actively dividing NARF2 cells, again revealing the dependence of CTGF expression on p53.
We also examined a p53-null Li-Fraumeni skin fibroblast cell line (MDAH-041) and MDAH-041 cells reconstituted with a tetracycline-regulated p53 cDNA (TR9-7, previously described by Agarwal et al., 1995) . The p53-null 041 cells express significantly less CTGF than TR9-7 cells, even when p53 is repressed ( þ tet). Additionally, TR9-7 cells display rapid induction of CTGF upon p53 induction (Àtet; Figures 6c and d) . Finally, loss of p53 expression in the 5-1 clone due to chemical mutagenesis also completely abrogates CTGF expression (Figures 6c and e) . Therefore, loss of p53 function results in increased cFABP and decreased CTGF expression in actively dividing cell populations. This observation argues that the changes in the expression of these genes are not due to changes in cell cycle distribution upon p53 induction. Also, while we have not distinguished between primary and secondary transcriptional events in this study, the loss of p53 in actively dividing cells mimics events in tumor progression due to the loss of p53, where changes in the expression of these genes become permanent. Based on the examination of large numbers of genes at one time and the arbitrary thresholds used to determine which genes were or were not regulated differentially, we are cautious regarding the status of genes that are apparently regulated similarly. We cannot rule out that our experimental parameters may have missed genes regulated in a phosphorylation-dependent manner.
Discussion
p53 phosphorylation does not enhance transactivation
Recent attention has focused on understanding the importance of oncogene-mediated p53 activation. Cellular proteins (MYC, RAS and E2F1) as well as viral proteins (adenoviral E1A and v-ABL) act by inducing the transcription of p14ARF, a negative regulator of MDM2 de Stanchina et al., 1998; Palmero et al., 1998; Zindy et al., 1998; Cong et al., 1999) . Given the importance of the p14ARF pathway in stabilizing p53, the lack of information regarding p53 modification and activity is somewhat surprising. Although it is well established that the expression of p14ARF induces p53 accumulation and activity, resulting in p53-dependent cell cycle arrest, few studies have examined the status of p53 following its accumulation in response to p14ARF. To uncover the differential regulation of genes following p53 induction by DNA damage or oncogene-mediated mechanisms, we used p14ARF induction as a model. The NARF2 cells used in this study undergo complete p53-dependent arrest upon p14ARF induction, similar to the effects of known physiological inducers of p14ARF.
p14ARF-mediated induction and adriamycin treatment stabilized p53 equivalently. While transactivation of p53 target genes p21 and mdm2 were also induced equivalently, the status of individual phosphorylation sites is strikingly contrasted when examined using phosphorylation site-specific antibodies. p53 was not phosphorylated detectably on any of the five N-terminal serine residues examined following p14ARF induction. Furthermore, p53-dependent transactivation for most of the genes examined was equivalent following stabilization by both treatments. When p53 was examined by two-dimensional Western analysis following p14ARF induction or adriamycin treatment, the abundance of p53 subspecies changed depending on the treatment used. There were noticeable increases in more negatively charged p53 molecules in response to adriamycin and noticeable increases in less negatively charged p53 molecules in response to p14ARF induction. However, nearly all of the p53 subspecies present in untreated cells remained following both treatments. Given that this assay does not distinguish between phosphorylation, acetylation, ubiquitination or sumoylation, we cannot conclude that changes in p53 charge are due to any specific modification. In addition, it is difficult to state conclusively how much of the total p53 is phosphorylated in experiments using phosphorylation-specific antibodies, although the amount phosphorylated in response to adriamycin treatment is enough to completely disrupt the p53-MDM2 interaction.
We also found that the p53 induced by p14ARF could not be rendered more active transcriptionally by additional treatment of the cells with adriamycin. This result is surprising, given that previous studies have demonstrated that phosphorylation of amino-terminal serine residues on p53 facilitates an interaction between p53 and p300/CBP (Lambert et al., 1998; Kar et al., 2002) as well as p53 and prolyl-isomerase Pin1 Zacchi et al., 2002; Zheng et al., 2002) . The observations presented here support recent findings that post-translational modification of p53 is not required for it to bind to DNA, as measured by chromatin immunoprecipitation (Kaeser and Iggo, 2002) or p53-dependent transcription (Espinosa and Emerson, 2001 ).
In these studies, p53 promoter occupancy in vivo correlated with changes in total p53 protein, supporting the notion that DNA damage and the resulting posttranslational modifications do not alter the affinity of p53 for DNA. Furthermore, unmodified p53 was able to bind to the p21 promoter and initiate the transcription of nucleosome-bound DNA, regardless of its acetylation/modification status (Espinosa and Emerson, 2001 ). The results presented here using p14ARF induction are consistent with previous studies from this lab using tetracycline-regulated p53 in TR9-7 cells (Agarwal et al., 1995) , where there is little detectable p53 phosphorylation upon tetracycline withdrawal (our unpublished observations; Xiao et al., 2000) , yet the elevation of p53 levels still arrests these cells efficiently (Agarwal et al., 1995) . Collectively, these observations argue against the need for p53 activation per se. Instead, much evidence argues that the level of p53 protein is the major determining factor for p53-mediated functions.
P53 stabilization via phosphorylation
Previous results from our lab and others clearly demonstrate that p53 can be stabilized in a transcriptionally inactive form following treatment with a PKC inhibitor, hydroxyurea or exposure to hypoxic conditions (Chernov et al.,. 2001; Gottifredi et al., 2001; Koumenis et al., 2001) . The PKC inhibitor H7 stabilizes p53 in an inactive complex with MDM2 (Chernov et al., 2001) . Thus, the key activating event for p53 seems to be its escape from MDM2-mediated inhibition. One way to dislodge MDM2 is by modifying it or p53. The need for modification of p53 in response to UV treatment was examined by stable, regulated expression of serine-or threonine-to-alanine mutants representing important Nterminal phosphorylation sites. The mutations alter p53 stability and ultimately its transcriptional activity by altering the strength of the p53 : MDM2 interaction Stark, 2001, 2002) . In addition, actinomycin D treatment stabilizes p53 in a transcriptionally active form, without phosphorylation of serines 15 and 20. In this case, p53 is stabilized due to changes in the subcellular localization of MDM2, with p53 remaining nuclear and MDM2 predominantly nucleolar, a phenomenon that is independent of p14ARF (Ashcroft et al., 2000) .
The fact that p14ARF can stabilize and activate p53-dependent transcription simply by inhibiting MDM2 in the absence of N-terminal phosphorylation, in conjunction with many other examples cited here, argues against the need for N-terminal phosphorylation events that activate transcription. Unlike serines 6, 9, 15, 20 and 37, phosphorylation of the C-terminal serine 392 cannot be ruled out as an important event in p14ARF-or adriamycin-mediated p53 activation, as it is phosphorylated by both treatments. Additionally, new sites of modification for p53 continue to be described, and modifications such as acetylation and sumoylation were not addressed in these studies and therefore their roles in p53 function in response to p14ARF induction and adriamycin treatment remain to be tested. Previous findings from this laboratory have implicated the phosphorylation of threonine 18 as an important step in activating p53-dependent transactivation in response to UV treatment (Bean and Stark, 2002 ). While we have not examined the phosphorylation of threonine 18 in this study (due to the lack of an appropriate antibody), it is unlikely to be involved in the p14ARF-induced activation of p53, primarily because serine 15, whose phosphorylation is a prerequisite for threonine 18 phosphorylation (Sakaguchi et al., 2000) , is not detectably modified following p14ARF induction. Additionally, our previous work relating the transcriptional activity of the T18A mutant of p53 in response to UV treatment did not examine whether the interaction between p53 and MDM2 was altered. The fact that threonine 18 phosphorylation has been described as a critical event for disrupting the p53-MDM2 interaction (Bottger et al., 1999; Sakaguchi et al., 2000) may explain the lack of p53-dependent transactivation previously described for the T18A mutant (Bean and Stark, 2002) . If the phosphorylation of threonine 18 were critical for disrupting the p53-MDM2 interaction, it would remain an important event for p53 transactivation in response to DNA damage, but would not be needed for p53 activity in response to p14ARF induction.
Gene-specific regulation by p14ARF or adriamycin
While the majority of genes were regulated similarly, we did find a few genes that were regulated differentially. Of particular interest, the expression of two genes previously identified as regulators of VEGF expression or activity were expressed in a p53-dependent manner following p14ARF induction. Cutaneous fatty acid binding protein (cFABP) was repressed and connective tissue growth factor (CTGF) was induced specifically, following induction of p53 by p14ARF, whereas adriamycin treatment did not alter their expression. Furthermore, the expression of GSE56, a genetic suppressor element that abrogates the activity of p53, in NARF2 cells, resulted in increased cFABP and decreased CTGF expression, arguing that their expression depends on p53 expression and activity.
Both proteins were described previously to be involved in regulating VEGF. cFABP can induce the metastasis of benign cells in an in vivo assay when overexpressed from a constitutive promoter (Jing et al., 2000) . The ability of cFABP to increase angiogenesis, invasion and metastasis is due to the significantly elevated VEGF production observed following cFABP expression, as the angiogenesis mediated by cFABP-expressing cells can be completely inhibited by an anti-VEGF neutralizing antibody (Jing et al., 2001) . CTGF is a member of the CCN gene family of secreted, modular proteins. Consistent with the p53-regulated induction observed here, CTGF inhibits the activities of VEGF. Inhibition of VEGF by CTGF involves a direct interaction between the two proteins that inhibits the ability of VEGF to bind to both of its receptors on endothelial cells as well as to soluble VEGF receptors, resulting in inhibition of VEGF-mediated angiogenesis (Inoki et al., 2002) .
Other genes of interest described here include components of the DNA replication machinery such as primase polypeptide 1 and replication factor C4; (RbAp48), an Rb-binding protein related to a negative regulator of ras in yeast called Rbbp4, HP10461 (also known as oncogene ECT2, which interacts with RHOlike proteins of the RAS superfamily), and PECC (preferentially expressed in colorectal cancer), a putative ATP/GTP-binding protein highly expressed in colorectal and lung carcinomas. All of the above genes are repressed specifically upon p14ARF induction in cells containing functional p53. They have not been previously linked to p53 expression. Therefore, the loss of p14ARF (or p53) would be likely to result in the enhanced expression of these newly identified, p53-regulated genes, many of which have roles in proliferation.
One potential reason for the difference in gene repression may be that downstream effectors are affected differentially. For example, in a recent study, adenoviral delivery of p14ARF into HCT116 cells was a more potent inhibitor of Rb phosphorylation than adriamycin, even though p21 was expressed equivalently and bromodeoxyuridine incorporation was inhibited similarly (Weber et al., 2002) . If the genes presented here are targets of Rb-mediated repression, perhaps differences in Rb phosphorylation reflect differences in its ability to function as a repressor. Alternatively, a recently reported complex among E2F4, p14ARF and p53 may enhance p53-mediated repression independently of transcription (Rizos et al., 2003) . This transcription-independent repressive mechanism may be gene-specific, as cdc2 and cyclin B1, two well-known targets of Rb-mediated repression , were regulated similarly in our experiments. Additionally, ESDN, a gene induced by both p14ARF expression and adriamycin treatment, has already been shown to inhibit bromodeoxyuridine incorporation when overexpressed (Kobuke et al., 2001) . Again, ESDN has not been described previously as a p53-responsive gene.
In conclusion, the studies presented here argue that p53 phosphorylation at specific N-terminal sites, while important for disrupting the p53-MDM2 interaction and ultimately increasing p53 protein levels, does not lead to greater transactivation of most p53-responsive genes. In fact, the differences in gene expression observed argue that less phosphorylated forms of p53 may repress specific genes more strongly. The differential expression of these genes may have biological importance in the regulation of VEGF and other proliferative signals and may provide insight into tumor behavior dependent upon p14ARF status.
Materials and methods
Cell culture
U2OS cells were obtained from the American Type Culture Collection, U2OS-NARF2 cells were a kind gift from Gordon , 1996) and pBabe-puro at a 10 : 1 ratio prior to selection in 1 mg/ ml puromycin (Sigma). TR9-7 cells have been described previously (Agarwal et al., 1995) . Mutant 5-1 cells resulted from a genetic screen in which chemical mutagenesis abrogated p53-dependent signaling (Agarwal et al., 2001) .
Western and Northern analysis
Whole cell protein extracts were prepared by incubating frozen cell pellets in an appropriate volume of single lysis buffer (50 mM Tris, pH 8.0,. 150 mM NaCl, 1.0% NP-40, 10 mg/ml aprotinin, 100 mg/ml PMSF, 5 mg/ml leupeptin, 5 mg/ml pepstatin and 1 mM sodium metavanadate). Protein concentrations were determined using a Bio-Rad Protein Assay (BioRad, Hercules, CA, USA), and equal amounts of protein were resolved by 12% SDS-PAGE, followed by transfer to a polyvinylidene difluoride membrane (Millipore) using the Transblot system (Bio-Rad, Hercules, CA, USA). Incubation with antibody was performed in 5% bovine serum albumin in PBST (1 Â PBS containing 0.05% Tween 20) for phosphospecific antibodies and in 5% non-fat dry milk in PBST for all other antibodies. Primary antibodies included the anti-p53 monoclonal DO-1-HRP and anti-p21 C-19-HRP (Santa Cruz Biochemicals, Santa Cruz, CA, USA), monoclonal anti-MDM2 antibodies 4B11 and 2A10 (Calbiochem), polyclonal anti-p14ARF Ab-1, monoclonal anti-Pan-actin (Neomarkers, Freemont, CA, USA), polyclonal antibodies against specific serines of p53 and a p53 polyclonal antibody to detect total p53 (Cell Signaling). An HRP-conjugated secondary antibody was used for chemiluminescent detection. Total RNA was isolated using the Trizol reagent (Gibco/ BRL, Gaithersburg, MD, USA). A 1% agarose gel containing 0.36% formaldehyde in MOPS buffer (200 mM 3[N-morpholino] propanesulfonic acid, 100 mM sodium acetate and 10 mM EDTA, pH 8.0) was used to resolve 10-20 mg of total RNA. The gels were transferred to a Hybond N þ nylon membrane and probed sequentially with 32 P-labeled cDNAs (Random Primer Labeling Kit, Amersham Biosciences) in Church Buffer (0.5 M sodium phosphate, pH 7.2, 1 mM EDTA, 7% (w/v) SDS and 1% (w/v) bovine serum albumin). Hybridized filters were washed twice with 1 Â SSC (150 mM sodium chloride, 15 mM sodium citrate), 0.1% SDS at 651C for 15 min each and once with 0.1 Â SSC (15 mM sodium chloride, 1.5 mM sodium citrate), 0.1% SDS at 651C. Membranes were exposed to Kodak XAR film for 12-48 h. For rehybridization, membranes were added to boiling 0.1% SDS and incubated at room temperature for 30 min to remove any residual 32 P-labeled probes.
Immunoprecipitations
These analyses were performed by incubating an equal amount of extract with 2 mg polyclonal p53 antibody C19 (Santa Cruz). Protein G-agarose (PGA, 25 ml of a 50% PBS slurry: Gibco BRL) was added to each reaction mixture, followed by incubation for 1 h more. The PGA:Ab complexes were washed three times in single lysis buffer (defined above) and resuspended in a 2 Â SDS gel loading buffer (100 mM Tris, pH 6.8, 4% (w/v) SDS, 20% glycerol, 200 mM b-mercaptoethanol and bromophenol blue). The proteins were analysed by the Western method.
Gene array and macroarray analyses
Using a range of different technologies, modes and times of induction of p53 and different cell types, several laboratories have identified many p53 target genes (Komarova et al.,. 1998; Zhao et al., 2000) . From a careful survey of the literature and from our own unpublished work, we have prepared a comprehensive p53-specific gene chip. We also included genes from the unpublished work of Erwin Van-Meir, Emory University (personal communication). cDNAs representing 1500 p53 target genes were obtained from Research Genetics/ Invitrogen in the form of bacterial cultures. The cDNAs were amplified and spotted on glass slides in duplicate using a robotic arrayer. Due to the number of inserts amplified, cDNAs were not verified by sequencing prior to spotting and array analysis. In all, 100 mg of total RNA was labeled by reverse transcription in the presence of Cy5 (red)-or Cy3 (green)-labeled nucleotides. Two labeled RNAs were competitively hybridized to the p53 array and the signals were analysed by using a laser scanner. Quantitation was performed by using Genespring and Excel Software.
Macroarray analysis was carried out using the protocol of Schlaak et al. (2002) . Briefly, cDNAs were amplified from bacterial clones using universal primers specific for the vector, gel purified and spotted in triplicate onto Hybond-N þ nylon membranes. Total RNA was purified from treated cells and labeled with 32 P-dCTP by reverse transcription before incubation with replicate membranes, using the same protocol as for Northern analyses. All washes were carried out as for Northern analyses. Quantitation was performed by using a PhosphoImager (Molecular Dynamics) and the results were analysed by using ImageQuant software.
